Elicio Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

ELTX$1.61-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

For the Six Months Ended June 30, 2026

Common Stock · Treasury Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders'Equity (Deficit)
Shares · Amount · Shares · Amount
Balance as of December 31, 2025	17,814,762	$178	(14,455)	$(150)	$235,407	$(127)	$(233,672)	$1,636
Issuance of common stock from at-the-market offering, net of issuance costs of $0.4 million	819,157	8	—	—	7,769	—	—	7,777
Issuance of common stock upon exercise of options	20,431	—	—	—	100	—	—	100
Stock-based compensation	—	—	—	—	868	—	—	868
Foreign currency translation adjustment	—	—	—	—	—	5	—	5
Net loss	—	—	—	—	—	—	(11,823)	(11,823)
Balance as of March 31, 2026	18,654,350	$186	(14,455)	$(150)	$244,144	$(122)	$(245,495)	$(1,437)
Exercise of stock options	3,059	—	—	—	17	—	—	17
Issuance of common stock from at-the-market offering, net of issuance costs of $0.5 million	3,258,615	33	—	—	16,610	—	—	16,643
Stock-based compensation	—	—	—	—	935	—	—	935
Foreign currency translation adjustment	—	—	—	—	—	(4)	—	(4)
Net loss	—	—	—	—	—	—	(8,217)	(8,217)
Balance as of June 30, 2026	21,916,024	$219	(14,455)	$(150)	$261,706	$(126)	$(253,712)	$7,937

For the Six Months Ended June 30, 2025

Common Stock · Treasury Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders'(Deficit) Equity
Shares · Amount · Shares · Amount
Balance as of December 31, 2024	11,043,837	$110	(14,455)	$(150)	$183,004	$(175)	$(194,101)	$(11,312)
Issuance of common stock from at-the-market offering, net of issuance costs	106,823	1	—	—	834	—	—	835
Issuance of common stock upon exercise of options	1,628	—	—	—	7	—	—	7
Conversion of senior note payable into common stock, net of issuance costs of $0.3 million	3,500,573	35	—	—	20,141	—	—	20,176
Issuance of common stock and warrants from the January 2025 Offering, net of issuance costs of $0.8 million	1,261,830	13	—	—	9,130	—	—	9,143
Issuance of common stock upon the exercise of common warrants	68,500	1	—	—	715	—	—	716
Stock-based compensation	—	—	—	—	517	—	—	517
Foreign currency translation adjustment	—	—	—	—	—	31	—	31
Net loss	—	—	—	—	—	—	(11,209)	(11,209)
Balance as of March 31, 2025	15,983,191	$160	(14,455)	$(150)	$214,348	$(144)	$(205,310)	$8,904
Issuance of common stock upon exercise of stock options	12,499	—	—	—	50	—	—	50
Issuance of common warrants associated with June 2025 Promissory Note	—	—	—	—	641	—	—	641
Issuance of common stock from at-the-market offering, net of issuance costs of $0.1 million	281,697	3	—	—	2,013	—	—	2,016
Stock-based compensation	—	—	—	—	710	—	—	710
Foreign currency translation adjustment	—	—	—	—	—	74	—	74
Net loss	—	—	—	—	—	—	(10,561)	(10,561)
Balance as of June 30, 2025	16,277,387	$163	(14,455)	$(150)	$217,762	$(70)	$(215,871)	$1,834

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.